{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:37:56Z","timestamp":1791275876348,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA41302, DA22177, DA40329, MH109385"],"award-info":[{"award-number":["DA41302, DA22177, DA40329, MH109385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00210","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T09:29:32Z","timestamp":1488792572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["IFN-\u03bb Inhibits Drug-Resistant HIV Infection of Macrophages"],"prefix":"10.3389","volume":"8","author":[{"given":"Xu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhe","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1002\/sim.1579","article-title":"Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies","volume":"23","author":"Cole","year":"2004","journal-title":"Stat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/med.20138","article-title":"HIV entry inhibitors and their potential in HIV therapy","volume":"29","author":"Qian","year":"2009","journal-title":"Med Res Rev"},{"key":"B3","first-page":"107","article-title":"2004: which HIV-1 drug resistance mutations are common in clinical practice?","volume":"6","author":"Cheung","year":"2004","journal-title":"AIDS Rev"},{"issue":"Suppl 1","key":"B4","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1097\/01.qai.0000137005.63376.6e","article-title":"Resistance issues with new nucleoside\/nucleotide backbone options","volume":"37","author":"Wainberg","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1128\/AAC.02012-12","article-title":"Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages","volume":"57","author":"Gavegnano","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11176","DOI":"10.1128\/JVI.01692-15","article-title":"Inhibition of HIV expression and integration in macrophages by methylglyoxal-bis-guanylhydrazone","volume":"89","author":"Jin","year":"2015","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11481-010-9256-1","article-title":"Tetherin and its viral antagonists","volume":"6","author":"Kuhl","year":"2011","journal-title":"J Neuroimmune Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2012-01-407395","article-title":"HIV-1 infection of human macrophages directly induces viperin which inhibits viral production","volume":"120","author":"Nasr","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-lambda 1: similarities with type I interferon signaling","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cyto.2005.04.003","article-title":"Biological activity of interleukins-28 and -29: comparison with type I interferons","volume":"31","author":"Meager","year":"2005","journal-title":"Cytokine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.4049\/jimmunol.180.4.2474","article-title":"An important role for type III interferon (IFN-lambda\/IL-28) in TLR-induced antiviral activity","volume":"180","author":"Ank","year":"2008","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/v2081589","article-title":"Interferon-lambda in HCV infection and therapy","volume":"2","author":"Pagliaccetti","year":"2010","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2002","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","article-title":"Lambda interferon inhibits hepatitis B and C virus replication","volume":"79","author":"Robek","year":"2005","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1128\/JVI.01773-08","article-title":"Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages","volume":"83","author":"Hou","year":"2009","journal-title":"J Virol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e35902","DOI":"10.1371\/journal.pone.0035902","article-title":"IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1089\/jir.2006.26.373","article-title":"IFN-lambda: novel antiviral cytokines","volume":"26","author":"Ank","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog"},{"key":"B22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/gene.2009.72","article-title":"Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines","volume":"10","author":"Witte","year":"2009","journal-title":"Genes Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.neuroscience.2008.12.036","article-title":"Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells","volume":"159","author":"Zhou","year":"2009","journal-title":"Neuroscience"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/glia.21076","article-title":"Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons","volume":"59","author":"Li","year":"2011","journal-title":"Glia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"suppl 1","key":"B28","doi-asserted-by":"publisher","first-page":"S438","DOI":"10.1007\/s12072-013-9429-0","article-title":"Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study","volume":"7","author":"Vierling","year":"2013","journal-title":"Hepatol Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14218\/JCTH.2013.00014","article-title":"Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic","volume":"1","author":"Andersen","year":"2013","journal-title":"J Clin Transl Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/jir.2014.0233","article-title":"Peginterferon lambda-1a is associated with a low incidence of autoimmune thyroid disease in chronic hepatitis C","volume":"35","author":"Fredlund","year":"2015","journal-title":"J Interferon Cytokine Res"},{"issue":"11","key":"B31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/jir.2015.0173","article-title":"Peginterferon lambda-1a\/ribavirin with daclatasvir or peginterferon alfa-2a\/ribavirin with telaprevir for chronic hepatitis C genotype 1b","volume":"36","author":"Flisiak","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2012.04.011","article-title":"IFN-lambda inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production","volume":"95","author":"Tian","year":"2012","journal-title":"Antiviral Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2353\/ajpath.2008.070971","article-title":"Methamphetamine enhances HIV infection of macrophages","volume":"172","author":"Liang","year":"2008","journal-title":"Am J Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2008-09-175000","article-title":"Cellular microRNA expression correlates with susceptibility of monocytes\/macrophages to HIV-1 infection","volume":"113","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/35091","article-title":"A new classification for HIV-1","volume":"391","author":"Berger","year":"1998","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.2467383","article-title":"HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy","volume":"243","author":"Larder","year":"1989","journal-title":"Science"},{"key":"B37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/JVI.62.1.139-147.1988","article-title":"In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity","volume":"62","author":"Willey","year":"1988","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1128\/JVI.66.1.573-579.1992","article-title":"Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1","volume":"66","author":"Ho","year":"1992","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1086\/338011","article-title":"Methadone enhances human immunodeficiency virus infection of human immune cells","volume":"185","author":"Li","year":"2002","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1097\/01.ALC.0000042148.50808.04","article-title":"Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes","volume":"26","author":"Wang","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2567.2010.03270.x","article-title":"A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages","volume":"131","author":"Zhou","year":"2010","journal-title":"Immunology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hep.22715","article-title":"CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes","volume":"49","author":"Ye","year":"2009","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajpath.2010.11.042","article-title":"Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes","volume":"178","author":"Wang","year":"2011","journal-title":"Am J Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature01707","article-title":"The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA","volume":"424","author":"Zhang","year":"2003","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1349-7006.2008.00968.x","article-title":"Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models","volume":"99","author":"Kawai","year":"2008","journal-title":"Cancer Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12542","article-title":"Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection","volume":"502","author":"Goujon","year":"2013","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature12653","article-title":"MX2 is an interferon-induced inhibitor of HIV-1 infection","volume":"502","author":"Kane","year":"2013","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chom.2013.08.015","article-title":"The interferon-inducible MxB protein inhibits HIV-1 infection","volume":"14","author":"Liu","year":"2013","journal-title":"Cell Host Microbe"},{"key":"B50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/jir.2014.0064","article-title":"Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages","volume":"35","author":"Wang","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ni0103-8","article-title":"Novel interferons","volume":"4","author":"Vilcek","year":"2003","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1189\/jlb.1208761","article-title":"Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses","volume":"86","author":"Li","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1074-7613(01)00169-8","article-title":"Crystal structure of the IL-10\/IL-10R1 complex reveals a shared receptor binding site","volume":"15","author":"Josephson","year":"2001","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/jir.2010.0058","article-title":"Interferon-lambda as a potential therapeutic agent in cancer treatment","volume":"30","author":"Steen","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"349575","DOI":"10.1155\/2011\/349575","article-title":"Interferon lambda: a new sword in cancer immunotherapy","volume":"2011","author":"Lasfar","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.gene.6364348","article-title":"Human interferon lambda-1 (IFN-lambda1\/IL-29) modulates the Th1\/Th2 response","volume":"8","author":"Jordan","year":"2007","journal-title":"Genes Immun"},{"key":"B57","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/1535-7163.MCT-09-0461","article-title":"Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis","volume":"9","author":"Guenterberg","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.gene.6364348","article-title":"Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1\/IL-29)","volume":"8","author":"Jordan","year":"2007","journal-title":"Genes Immun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"G960","DOI":"10.1152\/ajpgi.00126.2005","article-title":"IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression","volume":"289","author":"Brand","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.antiviral.2008.06.016","article-title":"Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus","volume":"80","author":"Almeida","year":"2008","journal-title":"Antiviral Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.antiviral.2009.03.006","article-title":"Antiviral effect of interferon lambda against West Nile virus","volume":"83","author":"Ma","year":"2009","journal-title":"Antiviral Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12985-015-0383-4","article-title":"Interferon lambda inhibits dengue virus replication in epithelial cells","volume":"12","author":"Palma-Ocampo","year":"2015","journal-title":"Virol J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/biof.19","article-title":"Type III IFNs: new layers of complexity in innate antiviral immunity","volume":"35","author":"Ank","year":"2009","journal-title":"Biofactors"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jicd.12200","article-title":"Association of interferon lambda-1 with herpes simplex viruses-1 and -2, Epstein-Barr virus, and human cytomegalovirus in chronic periodontitis","author":"Muzammil","year":"2015","journal-title":"J Investig Clin Dent"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1000151","DOI":"10.1371\/journal.ppat.1000151","article-title":"Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses","volume":"4","author":"Mordstein","year":"2008","journal-title":"PLoS Pathog"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J Virol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000360084","article-title":"Interferon-lambda in the context of viral infections: production, response and therapeutic implications","volume":"6","author":"Hermant","year":"2014","journal-title":"J Innate Immun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T11:12:57Z","timestamp":1601723577000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":68,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00210","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}